Overview

Optimize Metabolic Health with Precision Pharmacogenomics

Personalize GLP-1 therapies and weight management solutions to improve outcomes and reduce complications across your health system.

Schedule a Demo Contact us

Overview

Metabolic disorders—including obesity, type 2 diabetes, and related complications—require a highly individualized approach for effective and sustainable results. PGxAI's Metabolism module (PGxMetis™) leverages advanced pharmacogenomics and real-world data to guide therapy selection and dosing for GLP-1 receptor agonists, appetite suppressants, and other metabolic treatments. By aligning each patient's genetic profile with the right medication strategy, PGxMetis™ supports better glycemic control, targeted weight loss, and improved long-term health outcomes.

•

Covers a wide array of therapies, from GLP-1 agonists (e.g., semaglutide, liraglutide) to lipase inhibitors and anorexiants.

•

Integrates 12+ critical genetic markers associated with metabolic pathways and drug metabolism.

•

AI-driven insights updated in real time, enhancing efficacy while minimizing adverse effects.

Key Highlights

Serving every stakeholder in healthcare

Schedule a Demo Contact Us

Comprehensive GLP-1 Analysis

Evaluates genetic factors influencing response to semaglutide, liraglutide, and dual agonists like tirzepatide.

Customized Weight-Management Protocols

Integrates pharmacogenetic data for orlistat, phentermine-topiramate, and naltrexone-bupropion, ensuring efficient, personalized outcomes.

Reduced Adverse Events

Tailored dosing strategies help mitigate side effects such as gastrointestinal discomfort or hypoglycemia, improving patient adherence.

Reimbursable Testing

Many PGx analyses qualify under recognized CPT codes, streamlining billing for personalized metabolic care.

Clinical Impact

Maximize Clinical Impact with PGxAI

Schedule a Demo Contact Us

Precision-Guided Therapy Optimization

PGxAI mines genotype, phenotype, and comorbidity data in real time to recommend the optimal drug–dose pair at the first prescription. By accounting for actionable allelic variants and metabolic phenotypes, it minimizes trial-and-error titration and sharply reduces severe drug–gene and drug–drug interactions.

Superior Patient Outcomes & Experience

Genomically informed prescribing lowers adverse-event rates, accelerates therapeutic response, optimizes co-administered medications and boosts adherence. Patients spend less time managing side effects and more time benefiting from treatment, enhancing both clinical endpoints and satisfaction metrics across specialties.

Demonstrable Value-Based Performance

Fewer complications, shorter lengths of stay, and reduced readmissions translate into measurable gains on CMS and private-payer quality dashboards. Institutions leveraging PGxAI can document higher quality scores and capture value-based reimbursement upside while lowering total cost of care.

Seamless Team Integration & Scalability

The platform embeds directly into leading EHRs and e-prescribing systems, delivering concise, guideline-aligned reports that support rapid decision-making for multidisciplinary teams. Standardized APIs and CDS hooks allow effortless expansion from pilot units to enterprise-wide deployment without workflow disruption.

Drug Categories

PGxAI supports a range of metabolic and weight-management therapies

Schedule a Demo Contact Us

GLP-1 Receptor Agonists:

Semaglutide, Tirzepatide, Liraglutide

Gastrointestinal Lipase Inhibitors:

Orlistat

Anorexiants:

Phentermine-Topiramate, Naltrexone-Bupropion

Melanocortin Receptor Agonists:

Setmelanotide

Adjunctive Agents:

Caffeine, Ephedrine (if clinically appropriate). Each recommendation is grounded in validated genetic research (e.g., MC4R, FTO variants) and real-world clinical data.

Case Study

Evergreen Metabolic Center

Schedule a Demo Contact Us

Challenge

Low response rates to standard GLP-1 therapies and frequent dropout due to side effects.

Solution

PGxMetis™ integrated to identify optimal candidates for semaglutide vs. other GLP-1s, tailoring dosages based on genetic markers.

Results

35% improvement in average weight loss at 6 months, lower incidence of GI side effects, and higher patient retention.

What's next

Ready to Shape the Future of Precision Medicine?

Empower your metabolic care teams with AI-driven pharmacogenomics that minimize side effects, boost treatment efficacy, and transform patient outcomes.

Request a Demo

Explore PGxMetis™ in action for your metabolic workflows.